v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Revenues, net
Costs and expenses:    
General and administrative costs 1,654,031 615,483
Research and development costs 333,376 91,457
Total costs and expenses 1,987,407 706,940
Loss from operations (1,987,407) (706,940)
Other income (expenses):    
Interest Income 3,370 441
Interest Expense (3,096) (3,135)
Foreign currency gain (loss) (475) 79
Net loss (1,987,608) (709,555)
Series B Convertible Preferred Stock 8% cumulative dividend (17,882)
Non-controlling interest 63,932
Net loss attributable to common stockholders $ (1,941,558) $ (709,555)
Net loss per common share - basic $ (0.18) $ (0.29)
Net loss per common share - diluted $ (0.18) $ (0.29)
Weighted average common shares outstanding basic 10,889,003 2,471,513
Weighted average common shares outstanding diluted 10,889,003 2,471,513

Source